ClinicalTrials.gg
Active, not recruitingNCT05326230Updated Apr 15, 2026

A Clinical Study of the Paradise™ Renal Denervation System in Patients With Hypertension (RADIANCE-HTN DUO)

An interventional study of Paradise™ (PRDS-001) Renal Denervation Ultrasound System and Renal Angiogram in Hypertension, Vascular Diseases and Cardiovascular Diseases, sponsored by Otsuka Medical Devices Co., Ltd. Japan. Active, not recruiting at 51 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Otsuka Medical Devices Co., Ltd. Japan (part of Otsuka Holdings Co., Ltd.) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 142 studies in Hypertension with a site in Japan — 11 open to participants now, 17 under way, 8 of them phase 3. Hypertension · Japan.

Planned enrollment
80th of 125
154 · median 237
Started
2022
with 2 others
No phase
12 of 142
none open now
Primary completion
2026-12
later than 1 of 16 live
Registered
119th of 142
by date

Among the 142 studies in Hypertension with a site in Japan, this one is the 80th largest by planned enrollment of the 125 interventional ones that give a count, is one of 3 that started in 2022, is one of 12 with no phase, reaches primary completion later than 1 of the 16 other live ones, and was the 119th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

11 of the 142 studies in Hypertension with a site in Japan are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Hypertension with a site in Japan, or all of them as a file.
02

Study summary

To compare the antihypertensive effect of renal denervation with the Paradise™ system with that of a sham procedure in hypertensive patients receiving two antihypertensive drugs at the time of consent, and treated with a duo combination antihypertensive pill.

03

Conditions studied

  • Hypertension
  • Vascular Diseases
  • Cardiovascular Diseases

Keywords

  • Denervation
  • Hypertension
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have received antihypertensive treatment with two antihypertensive drugs (ARB/ACE inhibitor and Ca channel antagonist, either as a single agent or as a combination) for at least 4 weeks prior to obtaining consent, with no change in the type or dosage.
  • Patients with a mean seated office blood pressure of between 140 mmHg and 180 mmHg systolic and between 90 mmHg and 110 mmHg diastolic at screening visit.
  • Patients with a mean 24-hour ABPM (ambulatory blood pressure measurement) of between 130 mmHg and 170 mmHg systolic and between 80 mmHg and 105 mmHg diastolic at baseline visit

Exclusion criteria

Exclusion Criteria

  • Lacks appropriate renal artery anatomy for renal denervation
  • Secondary hypertension other than sleep apnea
  • Type 1 diabetes mellitus or uncontrolled Type 2 diabetes
  • Any history of cerebrovascular event or severe cardiovascular event, within 6 months prior to consent
  • Repeated hospitalization for hypertensive crisis (twice or more) within 12 months prior to obtaining consent, or any hospitalization for hypertensive crisis within 3 months prior to obtaining consent
  • Patients prescribed to drugs that have antihypertensive effects for other chronic diseases, and the investigator considers that discontinuation of these drugs may pose a serious risk to health
  • Patients who are taking drugs known to affect blood pressure and the investigator judges that it is not possible to discontinue these drugs during the study period
  • Patients with a history of persistent or permanent atrial tachyarrhythmia
  • Patients with active implantable medical devices
  • Primary pulmonary hypertension
  • Patients with or unacceptable anaphylactic reactions or uncontrolled allergy to contrast media
  • Night shift workers
  • Pregnant, nursing or planning to become pregnant
  • Patients with any of the following central laboratory tests at screening

    • Plasma aldosterone/renin ratio greater than or equal to 200 and plasma aldosterone greater than or equal to 60 pg/ml
    • greater than or equal to 8.0%
    • less than 40 mL/min/1.73m2
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
154 participants (estimated)

Study arms

  • Experimental
    Renal Denervation

    Renal Angiogram and Renal Denervation (PRDS-001- Paradise™ System)

    Device: Paradise™ (PRDS-001) Renal Denervation Ultrasound System

  • Sham comparator
    Sham Control

    Renal Angiogram

    Device: Renal Angiogram

Interventions

  • DeviceParadise™ (PRDS-001) Renal Denervation Ultrasound System

    Following renal angiogram according to standard procedures, subjects remain blinded and are randomized to treatment with renal denervation or sham control

    Also known as: Renal Angiogram/Renal Denervation

  • DeviceRenal Angiogram

    Following renal angiogram according to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure

06

What researchers measure

Primary outcomes

  1. Mean change in 24-hour systolic ABPM

    Time frame: From baseline to 3 months post-procedure

Secondary outcomes

  1. Mean change in 24-hour systolic ABPM

    Time frame: from baseline to 6 months post-procedure

  2. Mean change in daytime/nighttime /24-hour ABPM (systolic/diastolic) (excluding primary and important secondary endpoints)

    Time frame: From baseline to 3, 6, 12 months post-procedure

  3. Change in mean sitting office blood pressure (systolic/diastolic)

    Time frame: From baseline to 1, 2, 3, 4, 5, 6, 9, 12, 24, 36 months post-procedure

  4. Change in mean home blood pressure (systolic/diastolic)

    Time frame: From baseline to 1, 2, 3, 4, 5, 6, 9, 12, 24, 36 months post-procedure

  5. Percentage of subjects with a mean decrease in daytime/nighttime/24-hour systolic ABPM of ≥5 mmHg, ≥10 mmHg, and ≥15 mmHg

    Time frame: 3, 6, and 12months post-procedure

  6. Percentage of subjects who required a change in antihypertensive medication

    Time frame: at any time up to 12 months after the procedure

  7. Percentage of subjects who achieved blood pressure control without any change in antihypertensive medication

    Time frame: 3, 6, 12 months after the procedure

  8. Percentage of subjects whose blood pressure was controlled by changing antihypertensive medication

    Time frame: 3, 6, 12 months after the procedure

  9. Change in mean pulse pressure (difference between systolic and diastolic blood pressure) in the office, home, ABPM

    Time frame: 3, 6, 12 months after the procedure

  10. Change in mean heart rate in the office, home, ABPM

    Time frame: 3, 6, 12 months after the procedure

07

Study locations

51 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Dec 2026, 53 months after the start.

Of 95 industry-sponsored interventional studies with no phase under Hypertension, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 53 months is above that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2022
First posted
Apr 13, 2022
StartActual
Jul 1, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2032
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05326230
Responsible party
Sponsor
First posted
Apr 13, 2022
Start date
Jul 1, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2032 (estimated)
Last update
Apr 15, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion